Education
About Us
Working with TipRanks
Follow Us
Immunome (IMNM)
NASDAQ:IMNM
Total Valuation
Immunome has a market cap or net worth of $800.51M. The enterprise value is $6.77M.
Market Cap$800.51M
Enterprise Value$6.77M
Share Statistics
Immunome has 87,012,330 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding87,012,330
Owned by Insiders1.62%
Owned by Institutions41.54%
Financial Efficiency
Immunome’s return on equity (ROE) is -1.62 and return on invested capital (ROIC) is -164.41%.
Return on Equity (ROE)-1.62
Return on Assets (ROA)-1.22
Return on Invested Capital (ROIC)-164.41%
Return on Capital Employed (ROCE)-1.64
Revenue Per Employee69.02K
Profits Per Employee-2.24M
Employee Count131
Asset Turnover0.04
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Immunome is -2.13. Immunome’s PEG ratio is -0.02.
PE Ratio-2.13
PS Ratio0.00
PB Ratio1.61
Price to Fair Value3.44
Price to FCF-0.93
Price to Operating Cash Flow-0.93
PEG Ratio-0.02
Income Statement
In the last 12 months, Immunome had revenue of 9.04M and earned -292.96M in profits. Earnings per share was -5.00.
Revenue9.04M
Gross Profit9.04M
Operating Income-305.80M
Pretax Income-292.96M
Net Income-292.96M
EBITDA-151.35M
Earnings Per Share (EPS)-5.00
Cash Flow
In the last 12 months, operating cash flow was -152.68M and capital expenditures -8.92M, giving a free cash flow of -161.60M billion.
Operating Cash Flow-152.68M
Free Cash Flow-161.60M
Free Cash Flow per Share-1.86
Dividends & Yields
Immunome pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.86
52-Week Price Change-30.04%
50-Day Moving Average8.12
200-Day Moving Average10.62
Relative Strength Index (RSI)56.32
Average Volume (3m)902.84K
Important Dates
Immunome upcoming earnings date is Aug 13, 2025, TBA Not Confirmed.
Last Earnings DateMay 12, 2025
Next Earnings DateAug 13, 2025
Ex-Dividend Date―
Financial Position
Immunome as a current ratio of 4.08, with Debt / Equity ratio of 1.76%
Current Ratio4.08
Quick Ratio4.08
Debt to Market Cap<0.01
Net Debt to EBITDA0.92
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Immunome has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Immunome EV to EBITDA ratio is -3.20, with an EV/FCF ratio of -4.10.
EV to Sales53.56
EV to EBITDA-3.20
EV to Free Cash Flow-4.10
EV to Operating Cash Flow-4.37
Balance Sheet
Immunome has $317.32M in cash and marketable securities with $4.77M in debt, giving a net cash position of -$312.55M billion.
Cash & Marketable Securities$317.32M
Total Debt$4.77M
Net Cash-$312.55M
Net Cash Per Share-$3.59
Tangible Book Value Per Share$3.09
Margins
Gross margin is 0.00%, with operating margin of -3382.37%, and net profit margin of -3240.38%.
Gross Margin0.00%
Operating Margin-3382.37%
Pretax Margin-3240.38%
Net Profit Margin-3240.38%
EBITDA Margin-1674.08%
EBIT Margin-1697.33%
Analyst Forecast
The average price target for Immunome is $27.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$27.00
Price Target Upside193.48% Upside
Analyst ConsensusStrong Buy
Analyst Count7
Revenue Growth Forecast-13.76%
EPS Growth Forecast57.73%